477 related articles for article (PubMed ID: 23659733)
1. Pacemaker or defibrillator surgery without interruption of anticoagulation.
Birnie DH; Healey JS; Wells GA; Verma A; Tang AS; Krahn AD; Simpson CS; Ayala-Paredes F; Coutu B; Leiria TL; Essebag V;
N Engl J Med; 2013 May; 368(22):2084-93. PubMed ID: 23659733
[TBL] [Abstract][Full Text] [Related]
2. Continuing warfarin therapy is superior to interrupting warfarin with or without bridging anticoagulation therapy in patients undergoing pacemaker and defibrillator implantation.
Ahmed I; Gertner E; Nelson WB; House CM; Dahiya R; Anderson CP; Benditt DG; Zhu DW
Heart Rhythm; 2010 Jun; 7(6):745-9. PubMed ID: 20176137
[TBL] [Abstract][Full Text] [Related]
3. Cardiac rhythm device surgery with uninterrupted oral anticoagulation.
Tyagi G; Pai SM; Pai RG
Future Cardiol; 2013 Nov; 9(6):763-6. PubMed ID: 24180532
[TBL] [Abstract][Full Text] [Related]
4. Implantation of cardiac rhythm devices without interruption of oral anticoagulation compared with perioperative bridging with low-molecular weight heparin.
Tischenko A; Gula LJ; Yee R; Klein GJ; Skanes AC; Krahn AD
Am Heart J; 2009 Aug; 158(2):252-6. PubMed ID: 19619702
[TBL] [Abstract][Full Text] [Related]
5. Reduced-dose warfarin or interrupted warfarin with heparin bridging for pacemaker or defibrillator implantation: a randomized trial.
Schulman S; Healey JS; Douketis JD; Delaney J; Morillo CA
Thromb Res; 2014 Oct; 134(4):814-8. PubMed ID: 25127655
[TBL] [Abstract][Full Text] [Related]
6. Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: The BRUISE CONTROL-2 trial.
Essebag V; Healey JS; Ayala-Paredes F; Kalfon E; Coutu B; Nery P; Verma A; Sapp J; Philippon F; Sandhu RK; Coyle D; Eikelboom J; Wells G; Birnie DH
Am Heart J; 2016 Mar; 173():102-7. PubMed ID: 26920602
[TBL] [Abstract][Full Text] [Related]
7. Risk of pocket hematoma in patients on chronic anticoagulation with warfarin undergoing electrophysiological device implantation: a comparison of different peri-operative management strategies.
Proietti R; Porto I; Levi M; Leo A; Russo V; Kalfon E; Biondi-Zoccai G; Roux JF; Birnie DH; Essebag V
Eur Rev Med Pharmacol Sci; 2015 Apr; 19(8):1461-79. PubMed ID: 25967723
[TBL] [Abstract][Full Text] [Related]
8. Effect of Direct Oral Anticoagulants, Warfarin, and Antiplatelet Agents on Risk of Device Pocket Hematoma: Combined Analysis of BRUISE CONTROL 1 and 2.
Essebag V; Healey JS; Joza J; Nery PB; Kalfon E; Leiria TLL; Verma A; Ayala-Paredes F; Coutu B; Sumner GL; Becker G; Philippon F; Eikelboom J; Sandhu RK; Sapp J; Leather R; Yung D; Thibault B; Simpson CS; Ahmad K; Toal S; Sturmer M; Kavanagh K; Crystal E; Wells GA; Krahn AD; Birnie DH
Circ Arrhythm Electrophysiol; 2019 Oct; 12(10):e007545. PubMed ID: 31610718
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of continued-warfarin versus heparin-bridging therapy during pacemaker and defibrillator surgery.
Coyle D; Coyle K; Essebag V; Birnie DH; Ahmad K; Toal S; Sapp J; Healey JS; Verma A; Wells G; Krahn AD
J Am Coll Cardiol; 2015 Mar; 65(9):957-9. PubMed ID: 25744016
[No Abstract] [Full Text] [Related]
10. Cardiac resynchronization therapy device implantation in patients with therapeutic international normalized ratios.
Ghanbari H; Feldman D; Schmidt M; Ottino J; Machado C; Akoum N; Wall TS; Daccarett M
Pacing Clin Electrophysiol; 2010 Apr; 33(4):400-6. PubMed ID: 20180915
[TBL] [Abstract][Full Text] [Related]
11. Continuation of warfarin during pacemaker or implantable cardioverter-defibrillator implantation: a randomized clinical trial.
Cheng A; Nazarian S; Brinker JA; Tompkins C; Spragg DD; Leng CT; Halperin H; Tandri H; Sinha SK; Marine JE; Calkins H; Tomaselli GF; Berger RD; Henrikson CA
Heart Rhythm; 2011 Apr; 8(4):536-40. PubMed ID: 21147261
[TBL] [Abstract][Full Text] [Related]
12. No increased bleeding events with continuation of oral anticoagulation therapy for patients undergoing cardiac device procedure.
Li HK; Chen FC; Rea RF; Asirvatham SJ; Powell BD; Friedman PA; Shen WK; Brady PA; Bradley DJ; Lee HC; Hodge DO; Slusser JP; Hayes DL; Cha YM
Pacing Clin Electrophysiol; 2011 Jul; 34(7):868-74. PubMed ID: 21410724
[TBL] [Abstract][Full Text] [Related]
13. Dual antiplatelet therapy and heparin "bridging" significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation.
Tompkins C; Cheng A; Dalal D; Brinker JA; Leng CT; Marine JE; Nazarian S; Spragg DD; Sinha S; Halperin H; Tomaselli GF; Berger RD; Calkins H; Henrikson CA
J Am Coll Cardiol; 2010 May; 55(21):2376-82. PubMed ID: 20488310
[TBL] [Abstract][Full Text] [Related]
14. Frequency of "Pocket" Hematoma in Patients Receiving Vitamin K Antagonist and Antiplatelet Therapy at the Time of Pacemaker or Cardioverter Defibrillator Implantation (from the POCKET Study).
Malagù M; Trevisan F; Scalone A; Marcantoni L; Sammarco G; Bertini M
Am J Cardiol; 2017 Apr; 119(7):1036-1040. PubMed ID: 28153344
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of safety and efficacy of uninterrupted warfarin compared to heparin-based bridging therapy during implantation of cardiac rhythm devices.
Ghanbari H; Phard WS; Al-Ameri H; Latchamsetty R; Jongnarngsin K; Crawford T; Good E; Chugh A; Oral H; Bogun F; Morady F; Pelosi F
Am J Cardiol; 2012 Nov; 110(10):1482-8. PubMed ID: 22906894
[TBL] [Abstract][Full Text] [Related]
16. The relationship between warfarin, aspirin, and clopidogrel continuation in the peri-procedural period and the incidence of hematoma formation after device implantation.
Thal S; Moukabary T; Boyella R; Shanmugasundaram M; Pierce MK; Thai H; Goldman S
Pacing Clin Electrophysiol; 2010 Apr; 33(4):385-8. PubMed ID: 20059711
[TBL] [Abstract][Full Text] [Related]
17. Concomitant anti-platelet therapy in warfarin-treated patients undergoing cardiac rhythm device implantation: A secondary analysis of the BRUISE CONTROL trial.
Essebag V; AlTurki A; Proietti R; Healey JS; Wells GA; Verma A; Krahn AD; Simpson CS; Ayala-Paredes F; Coutu B; Leather R; Ahmad K; Toal S; Sapp J; Sturmer M; Kavanagh K; Crystal E; Leiria TLL; Seifer C; Rinne C; Birnie D;
Int J Cardiol; 2019 Aug; 288():87-93. PubMed ID: 31056413
[TBL] [Abstract][Full Text] [Related]
18. Bleeding risk of submuscular ICD implantation with continued oral anticoagulation versus heparin bridging therapy.
Pecha S; Ayikli A; Wilke I; Hakmi S; Yildirim Y; Gosau N; Reichenspurner H; Willems S; Aydin MA
Heart Vessels; 2018 Apr; 33(4):441-446. PubMed ID: 29030709
[TBL] [Abstract][Full Text] [Related]
19. Thrombocytopenia, dual antiplatelet therapy, and heparin bridging strategy increase pocket hematoma complications in patients undergoing cardiac rhythm device implantation.
Chen HC; Chen YL; Guo BF; Tsai TH; Chang JP; Pan KL; Lin YS; Chen MC
Can J Cardiol; 2013 Sep; 29(9):1110-7. PubMed ID: 23474139
[TBL] [Abstract][Full Text] [Related]
20. Management of Perioperative Anticoagulation for Device Implantation.
Stewart MH; Morin DP
Card Electrophysiol Clin; 2018 Mar; 10(1):99-109. PubMed ID: 29428146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
